Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Net Income | -- | -96.53% | -171.87% | -502.01% | -883.59% |
| Total Depreciation and Amortization | -- | -192.83% | 27.09% | -12.15% | -35.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 144.21% | 216.61% | 678.50% | 1,007.59% |
| Change in Net Operating Assets | -- | 381.48% | -389.57% | 178.06% | -405.51% |
| Cash from Operations | -- | 151.54% | -76.55% | -69.68% | -555.72% |
| Capital Expenditure | -- | 60.38% | 89.72% | 82.48% | 46.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -56.65% | 29.93% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 104.19% | 112.87% | -792,083.33% | -788,933.33% |
| Cash from Investing | -- | 55.05% | 106.06% | -2,714.85% | -3,635.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -98.04% | -88.39% | 45.33% | 1,210.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -98.11% | -88.67% | 44.68% | 1,185.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -158.43% | -147.30% | -169.69% | 621.25% |
